Search research articles
Contact Us
Filters
Showing results (111-120 of 257) with videos related to
Page
of 26
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
February 5, 2013
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients
Brooke M Emerling, Cyril H Benes, George Poulogiannis, et al.
Oncotarget
|
June 2, 2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
Xiaoen Wang, Nicolas Solban, Prateek Khanna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2014
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial
Toni K Choueiri, David J Figueroa, André P Fay, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 18, 2014
GRK3 is essential for metastatic cells and promotes prostate tumor progression
Wenliang Li, Nanping Ai, Suming Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy
David J Einstein, Brian Halbert, Thomas Denize, et al.
Plos One
|
May 12, 2011
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
Liang Zhang, Manoj Bhasin, Rachel Schor-Bardach, et al.
Cancer
|
May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
Rana R McKay, Guillermo De Velasco, Lillian Werner, et al.
Molecular Cancer Therapeutics
|
October 27, 2019
Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Amin H Nassar, Lana Hamieh, Kathryn P Gray, et al.
Cell Reports. Medicine
|
February 22, 2023
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
Julie Stein Deutsch, Evan J Lipson, Ludmila Danilova, et al.
Nature Genetics
|
May 31, 2016
Landscape of tumor-infiltrating T cell repertoire of human cancers
Bo Li, Taiwen Li, Jean-Christophe Pignon, et al.
Page
of 26
Search research articles
Search
Showing results (111-120 of 257) with videos related to
Sort By:
Page
of 26
Proceedings of the National Academy of Sciences of the United States of America
|
February 5, 2013
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients
Brooke M Emerling, Cyril H Benes, George Poulogiannis, et al.
Oncotarget
|
June 2, 2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
Xiaoen Wang, Nicolas Solban, Prateek Khanna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2014
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial
Toni K Choueiri, David J Figueroa, André P Fay, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 18, 2014
GRK3 is essential for metastatic cells and promotes prostate tumor progression
Wenliang Li, Nanping Ai, Suming Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy
David J Einstein, Brian Halbert, Thomas Denize, et al.
Plos One
|
May 12, 2011
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
Liang Zhang, Manoj Bhasin, Rachel Schor-Bardach, et al.
Cancer
|
May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
Rana R McKay, Guillermo De Velasco, Lillian Werner, et al.
Molecular Cancer Therapeutics
|
October 27, 2019
Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Amin H Nassar, Lana Hamieh, Kathryn P Gray, et al.
Cell Reports. Medicine
|
February 22, 2023
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
Julie Stein Deutsch, Evan J Lipson, Ludmila Danilova, et al.
Nature Genetics
|
May 31, 2016
Landscape of tumor-infiltrating T cell repertoire of human cancers
Bo Li, Taiwen Li, Jean-Christophe Pignon, et al.
Page
of 26